IL279220B2 - Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders - Google Patents

Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders

Info

Publication number
IL279220B2
IL279220B2 IL279220A IL27922020A IL279220B2 IL 279220 B2 IL279220 B2 IL 279220B2 IL 279220 A IL279220 A IL 279220A IL 27922020 A IL27922020 A IL 27922020A IL 279220 B2 IL279220 B2 IL 279220B2
Authority
IL
Israel
Prior art keywords
per day
pharmaceutically acceptable
acceptable salt
amino
syndrome
Prior art date
Application number
IL279220A
Other languages
English (en)
Hebrew (he)
Other versions
IL279220A (en
IL279220B1 (en
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL279220A publication Critical patent/IL279220A/en
Publication of IL279220B1 publication Critical patent/IL279220B1/en
Publication of IL279220B2 publication Critical patent/IL279220B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL279220A 2018-06-07 2019-06-07 Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders IL279220B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862681913P 2018-06-07 2018-06-07
PCT/US2019/035934 WO2019236938A1 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Publications (3)

Publication Number Publication Date
IL279220A IL279220A (en) 2021-01-31
IL279220B1 IL279220B1 (en) 2023-08-01
IL279220B2 true IL279220B2 (en) 2023-12-01

Family

ID=68765508

Family Applications (2)

Application Number Title Priority Date Filing Date
IL279220A IL279220B2 (en) 2018-06-07 2019-06-07 Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders
IL304270A IL304270B2 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL304270A IL304270B2 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Country Status (12)

Country Link
US (3) US10813899B2 (cg-RX-API-DMAC10.html)
EP (1) EP3813816B1 (cg-RX-API-DMAC10.html)
JP (1) JP7387179B2 (cg-RX-API-DMAC10.html)
KR (1) KR102744830B1 (cg-RX-API-DMAC10.html)
CN (1) CN112770739B (cg-RX-API-DMAC10.html)
AU (1) AU2019280980B2 (cg-RX-API-DMAC10.html)
CA (1) CA3102786A1 (cg-RX-API-DMAC10.html)
ES (1) ES2948263T3 (cg-RX-API-DMAC10.html)
IL (2) IL279220B2 (cg-RX-API-DMAC10.html)
MX (2) MX2020013290A (cg-RX-API-DMAC10.html)
PL (1) PL3813816T3 (cg-RX-API-DMAC10.html)
WO (1) WO2019236938A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
WO2020039262A1 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
IL322802A (en) 2023-02-17 2025-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of gastrointestinal disorders and as an immunomodulatory agent
US20240285565A1 (en) 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
US20260130878A1 (en) * 2024-11-12 2026-05-14 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
WO2005120496A2 (en) 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
WO2009033818A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2013112363A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
TW201606304A (zh) * 2013-09-09 2016-02-16 亞克柏拉有限公司 測定治療反應之方法
US20150224164A1 (en) 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
AU2015342801A1 (en) 2014-11-07 2017-05-18 Hadasit Medical Research Services And Development Ltd. Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
CN108137484B (zh) * 2015-10-09 2021-02-12 西北大学 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物
US10632088B2 (en) 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
KR20240110989A (ko) * 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들
US20200268711A1 (en) * 2017-11-14 2020-08-27 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome
JP7475055B2 (ja) 2018-05-25 2024-04-26 ノースウェスタン ユニバーシティ (s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸の合成法
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Also Published As

Publication number Publication date
MX2020013290A (es) 2021-04-29
KR102744830B1 (ko) 2024-12-19
JP7387179B2 (ja) 2023-11-28
IL304270B2 (en) 2024-10-01
US20190374492A1 (en) 2019-12-12
IL304270B1 (en) 2024-06-01
KR20210035802A (ko) 2021-04-01
EP3813816A1 (en) 2021-05-05
CA3102786A1 (en) 2019-12-12
IL304270A (en) 2023-09-01
CN112770739B (zh) 2023-12-12
IL279220A (en) 2021-01-31
US11660277B2 (en) 2023-05-30
IL279220B1 (en) 2023-08-01
EP3813816A4 (en) 2021-06-23
US12285397B2 (en) 2025-04-29
AU2019280980B2 (en) 2025-02-27
EP3813816B1 (en) 2023-06-07
US10813899B2 (en) 2020-10-27
CN112770739A (zh) 2021-05-07
AU2019280980A1 (en) 2021-01-07
MX2023006497A (es) 2023-06-21
JP2021527053A (ja) 2021-10-11
WO2019236938A1 (en) 2019-12-12
US20230255914A1 (en) 2023-08-17
US20210100763A1 (en) 2021-04-08
EP3813816C0 (en) 2023-06-07
PL3813816T3 (pl) 2023-07-31
ES2948263T3 (es) 2023-09-07

Similar Documents

Publication Publication Date Title
IL279220B1 (en) Use of (s)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1s, 3s)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders
US12465597B2 (en) Methods of treating developmental disorders with gaboxadol
CA2580619C (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
US20190328719A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
IL297642A (en) Methods for using t-type calcium channel modulators
KR20200146038A (ko) 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물
WO2020018779A1 (en) Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
HK40050398B (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
HK40050398A (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
AU2011235981B2 (en) Use of Memantine (Namenda) to Treat Autism, Compulsivity, and Impulsivity
WO2005027968A1 (ja) ダウン症候群治療剤
HK40012437A (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine